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Dear Sir,
We read with interest the article by Assidi et al. “Key ele-
ments of preparedness for pandemic coronavirus disease 2019
(COVID-19) in nuclear medicine units” [1]. The authors de-
scribe general recommendations for nuclear medicine units
during COVID-19, including the use of personal protective
equipment and management of patients and environmental
hygiene.
The authors also recommend to postpone any therapeutic
procedure with radiopharmaceuticals according to clinical
need. The pandemic of SARS-CoV-2 disease is one of the
biggest challenges in the recent history of medicine and the
effects on the healthcare systems worldwide will be noticeable
for many years. However, treatment of patients with malig-
nant disease remains crucial for their very survival. As our
institute is one of the largest peptide receptor radionuclide
therapy (PRRT) centres in Europe, providing PRRT for the
major i ty of neuroendocr ine tumour pa t i en t s in
The Netherlands, a complete stop of patients for several
months could have detrimental health effects for our patients.
The COVID-19 epidemic in The Netherlands started on
February 27, 2020, with the first documented patient and has
since led to 43,481 confirmed infections and 5590 casualties
caused by COVID-19 (dated May 14, 2020).
Since the start of the pandemic in The Netherlands, we
have continued clinical treatment with 177Lu-DOTATATE,
iodine-131 and radioembolization with yttrium-90 for indica-
tions of malignant disease. Our revised protocol established
onMarch 16 included calling patients before admission to ask
for the existence of respiratory symptoms or fever, in which
case treatment would be postponed. Patients arrived at the
treatment facility alone and were confined to their individual
rooms during the overnight admission. Staff and nurses in-
creased their use of personal protective equipment and envi-
ronmental hygiene around patients.
Between February 27 and May 14, a total of 107 cycles of
177Lu-DOTATATE was administered to 83 individual pa-
tients at our centre. In that same period, 21 patients received
iodine-131 and 7 pat ients underwent yt tr ium-90
radioembolization. During admission, only one patient devel-
oped transient respiratory symptoms and fever after treatment
with radioiodine. He was tested SARS-CoV-2 negative on
nasal swab and had no COVID-related abnormalities on chest
CT. In follow-up, one of our PRRT patients was admitted to
the hospital with COVID-19-induced immune thrombocyto-
penia (ITP), after being infected by his spouse [2]. None of
other patients treated with 177Lu-DOTATATE, iodine-131 or
yttrium-90 radioembolization developed COVID-19 during
follow-up.
Radionuclide therapy has not been shown to increase sus-
ceptibility to or complication risk of viral infections. In our
previous series of 610 patients receiving PRRT because of
advanced neuroendocrine tumours, transient CTCAE grade
3/4 lymphopenia occurred in 50% but were not accompanied
with the occurrence of severe viral infections. In recently
emerging data on COVID-19, patients with cancer appear to
have an increased risk of worse outcome, particularly in met-
astatic stages [3]. The additional risk appears limited in pa-
tients with thyroid cancer and those treated with radiation
therapy.
The possible consequences of postponing therapeutic pro-
cedures with radiopharmaceuticals for patients with malignant
disease should be individually weighed against the possible
risk of a COVID-19 infection during radionuclide therapy.
Our experience in a large PRRT centre in The Netherlands
demonstrates that it is safe to continue radionuclide therapy
amidst the COVID-19 epidemic when using the right
precautions.
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